Angiofollicular Lymph Hyperplasia - 22 Studies Found
| Active, not recruiting |
: A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease : Multicentric Castleman's Disease : 2011-04-21 : Drug: Siltuximab Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. |
| Completed |
: A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment : Castleman's Disease : 2010-08-13 : Drug: tocilizumab [RoActemra/Actemra] maintenance dose |
| Active, not recruiting |
: A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease : Multicentric Castleman's Disease : 2009-11-30 :
|
| Withdrawn |
: Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease : Giant Lymph Node Hyperplasia : 2006-08-08 : Drug: Valganciclovir valganciclovir open label, two 450mg tablets orally, twice a day |
| Recruiting |
: Tocilizumab for KSHV-Associated Multicentric Castleman Disease :
|
| Recruiting |
: TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial : Multicentric Castleman Disease : 2017-01-31 : Drug: Thalidomide, cyclophosphamide and prednisone |
| Terminated |
: Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy :
: 2005-08-04 : Drug: Rituximab |
| Recruiting |
: Unlock the Cell: Castleman's Disease Flow Cytometry Study :
|
| Recruiting |
: Castleman Disease Collaborative Network Biobank :
|
| Completed |
: A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease :
|